- Conditions
- Berylliosis, Beryllium Disease
- Interventions
- Infliximab, Placebo
- Drug · Other
- Lead sponsor
- Maier, Lisa, M.D.
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Denver, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 596
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
- Interventions
- CryoSpray Ablation
- Device
- Lead sponsor
- CSA Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Fibrotic Interstitial Lung Disease
- Interventions
- Pulmonary Rehabilitation
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Not listed
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Saracatinab, Placebo
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Pharmacokinetic Study, Ulixertinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- HEC585
- Drug
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Interstitial Lung Disease
- Interventions
- Trans Sodium Crocetinate, Placebo
- Drug
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- SAR156597, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more
- Conditions
- Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Hypoxemia
- Interventions
- Portable Oxygen Concentrator, Portable compressed oxygen D-tanks, No ambulatory oxygen therapy
- Device · Other
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Interstitial Lung Disease
- Interventions
- ⁶⁸Ga-FAPI-46, PET/CT
- Drug · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hermansky Pudlak Syndrome, Interstitial Lung Disease
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Jesse Roman
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis, Asthma, Sarcoidosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Yoga
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
- Interventions
- Inhaled Nitric Oxide
- Drug
- Lead sponsor
- Geno LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo
- Drug
- Lead sponsor
- aTyr Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Healthy
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- ACT-064992 (macitentan), Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
- Interventions
- Tazemetostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Gastro Esophageal Reflux
- Interventions
- Positive Airway Pressure
- Device
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Stanford, California + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 781 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more